New dry eye treatment put to the test against current standard

NCT ID NCT05865457

Recruiting now Symptom relief Sponsor: TRB Chemedica International SA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new treatment (BUFY02) works as well as an existing one (TRB02) for dry eye disease. About 80 adults with dry eye for at least 3 months will use the assigned eye drops daily for 3 months. Researchers will check eye health and symptoms to see if both treatments are similarly effective and safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE DISEASE

Contacts and locations

Locations

CHRU Brest
RECRUITING

Brest, France
CHU Nice
RECRUITING

Nice, France
Hôpital Bicêtre
RECRUITING

Le Kremlin-Bicêtre, France
Medical University Graz
RECRUITING

Graz, Austria
VIROS
RECRUITING

Vienna, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.